Clinical trials: malaria
Malaria
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults.
- Trial name
- NCT01024686
- Testing
- p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Malaria
Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults
The primary objective of the study is to evaluate the safety of 3 different dosages (20µg - 50µg and 100µg) of a placental malaria vaccine candidate (PRIMVAC vaccine) adjuvanted either with Alhydrogel® or GLA-SE, and administered…
- Trial name
- PRIMALVAC (NCT02658253)
- Testing
- PRIMVAC, GLA-SE, Alhydrogel
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Plasmodium Falciparum Infection
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To show the contribution of artefenomel (OZ439) to the clinical and parasiticidal effect of OZ439/Ferroquine (FQ) combination by analyzing exposure-response of OZ439 measured by Day 28 polymerase chain reaction…
- Trial name
- NCT03660839
- Testing
- Artefenomel (OZ439), Ferroquine (SSR97193)
- Where
- 7 sites in Benin, Burkina Faso and 3 more
- Volunteers
- 140 people
- Sponsor
- Sanofi
Malaria
A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Plasmodium falciparum (Pf) malaria remains a major cause of morbidity and mortality worldwide. A malaria vaccine would contribute towards efforts to control and eliminate malaria.
- Trial name
- NCT01322581
- Where
- Mali
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Plasmodium Falciparum
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Malaria is one of the major infectious diseases in the world with a tremendous impact on the quality of life, significantly contributing to the ongoing poverty in endemic countries.
- Trial name
- NCT01422954
- Testing
- Chloroquine prophylaxis, Mefloquine prophylaxis, Immunization
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Folic Acid Supplementation in Gambian Primigravidae
Supplementation with folic acid and iron is recommended for pregnant women in order to prevent them from developing anemia. In malaria endemic areas of Africa, the World Health Organization (WHO) now recommends that pregnant…
- Trial name
- NCT00120822
- Testing
- Folic acid
- Where
- The Gambia
- Volunteers
- 1,000 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.
- Trial name
- NCT06294912
- Testing
- Plasmodium falciparum, MK-7602, Artemether/lumefantrine
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malaria
Blood-Stage Plasmodium Vivax Cell Bank
Background: Malaria is caused by a parasite (a type of germ called P. vivax) that is carried by mosquitoes. The disease is transmitted to people when they are bitten by infected mosquitoes.
- Trial name
- NCT05095272
- Testing
- HMPBS02-Pv
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Malaria Infection
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and…
- Trial name
- NCT05974267
- Testing
- M5717 60 mg, Pyronaridine, Atovaquone-Proguanil
- Where
- 4 sites in Burkina Faso, Kenya and 2 more
- Volunteers
- 192 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Bioavailability
Atoguanil BA Study
This trial aims to characterise the pharmacokinetic (PK) profile and estimate drug exposure from Atoguanil in comparison to Malarone®.
- Trial name
- NCT04866602
- Testing
- Atoguanil, Malarone
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Falciparum, Malaria, Vivax
A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.
The primary aim of the comparative trial is to assess the relative safety and efficacy of two artemisinin containing regimens: amodiaquine plus artesunate (AAQ) and artekin both administered once daily for 3 days.
- Trial name
- NCT00157885
- Testing
- Amodiaquine plus artesunate; Artekin
- Where
- Indonesia
- Volunteers
- 400 people
- Sponsor
- Menzies School of Health Research
Bloodstream Infection, Salmonella Bacteremia
Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%).
- Conditions
- Bloodstream Infection, Salmonella Bacteremia, Malaria,Falciparum, Severe Malaria
- Trial name
- DeNTS (NCT04473768)
- Where
- Belgium
- Volunteers
- 1,880 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Uncomplicated
Adherence to Lumefantrine-Artemether
This is a study of how well caregivers of children with malaria adhere to the recommended regimen for lumefantrine-artemether (LA).
- Trial name
- NCT00153491
- Testing
- artemether-lumefantrine
- Where
- Tanzania
- Volunteers
- 300 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
School-based Programme of Malaria Diagnosis and Treatment in Southern Malawi
Malaria is an important contributor to ill-health experienced by school-children and may have profound consequences for their learning and educational achievement, and there is a small, but growing, body of evidence that suggests…
- Trial name
- NCT02213211
- Testing
- Artemether lumefantrine
- Where
- Malawi
- Volunteers
- 3,667 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Drug Resistant Malaria, Asymptomatic Infections
Drug Resistance Among Asymptomatic Infection
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
- Conditions
- Drug Resistant Malaria, Asymptomatic Infections, Migrant Workers
- Trial name
- NCT03648411
- Testing
- Drug resistance molecular markers
- Where
- Burma
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Malaria
R21/Matrix-M in African Children Against Clinical Malaria
A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
- Trial name
- NCT04704830
- Testing
- R21/Matrix-M, Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine
- Where
- United Kingdom
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Human Mass Balance Study of Pyronaridine
The combination of pyronaridine and artesunate is an antimalarial therapy in development. This mass balance study is intended to determine the rate and extent of excretion of total radioactivity in urine and feces following…
- Trial name
- NCT01383109
- Testing
- 14C-labeled Pyronaridine
- Where
- Switzerland
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Innovation Platform
In this study, a prospective evaluation of novel malaria diagnostic tools under development will be performed in malaria-endemic countries to assess their clinical performance for detection of malaria at point-of-care (POC).
- Trial name
- NCT04558528
- Testing
- Novel in vitro diagnostics and medical applications
- Where
- 2 sites in Indonesia, Rwanda
- Volunteers
- 640 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria
Preventing the Spread of Malaria in Mali
A vaccine which interrupts malaria transmission is a critical tool to achieve the ultimate goal of eradication of this disease. Transmission blocking vaccines work by inducing antibody in vaccinated individuals that inhibits the…
- Trial name
- NCT01360112
- Where
- Mali
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.